Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: a tripartite comparison

This analysis of 14 type 2 diabetes medicines and their associated cardiovascular outcomes trials found substantial differences between Japan and the US and EU in terms of the corresponding regulatory decisions, suggesting different interpretation of trial data in these regions.

British Journal of Clinical Pharmacology